Twenty-six patients presenting with advanced breast cancer with a taxane- and vinorelbine-free line of chemotherapy were included and treated with vinorelbine ( 20 mg/m2 on D1 , D15 ) , followed by paclitaxel ( 175 mg/m2 on D1 ) , every 3 weeks .
Phase II study of paclitaxel combined with vinorelbine in patients with advanced breast cancer. paclitaxel and vinorelbine are two drugs active against breast cancer. A phase II study was initiated with the aim of assessing the efficacy and feasibility of the combination. Twenty-six patients presenting with advanced breast cancer with a taxane- and vinorelbine-free line of chemotherapy were included and treated with vinorelbine ( 20 mg/m2 on D1 , D15 ) , followed by paclitaxel ( 175 mg/m2 on D1 ) , every 3 weeks . A 48% (95% CI: 35-61) response rate was obtained in the 23 patients evaluable for response. vinorelbine was administered on D15, as scheduled, in 72% of cycles. The main toxicity observed was grade III to IV neutropenia in 73% of patients. Febrile neutropenia was reported in three patients. Disease-free survival was 118 days, and overall median survival was 361 days. This combination of paclitaxel and vinorelbine is feasible and effective in patients with early relapse or previously treated with first-line chemotherapy for metastatic disease.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Phase II study of paclitaxel combined with vinorelbine in patients with advanced breast cancer. paclitaxel and vinorelbine are two drugs active against breast cancer. A phase II study was initiated with the aim of assessing the efficacy and feasibility of the combination. Twenty-six patients presenting with advanced breast cancer with a taxane- and vinorelbine-free line of chemotherapy were included and treated with vinorelbine ( 20 mg/m2 on D1 , D15 ) , followed by paclitaxel ( 175 mg/m2 on D1 ) , every 3 weeks . A 48% (95% CI: 35-61) response rate was obtained in the 23 patients evaluable for response. vinorelbine was administered on D15, as scheduled, in 72% of cycles. The main toxicity observed was grade III to IV neutropenia in 73% of patients. Febrile neutropenia was reported in three patients. Disease-free survival was 118 days, and overall median survival was 361 days. This combination of paclitaxel and vinorelbine is feasible and effective in patients with early relapse or previously treated with first-line chemotherapy for metastatic disease.

            ### Response:
            vinorelbine, paclitaxel
            